Abstract
Claims about cannabidiol (CBD) supplementation improving health and behavior are extensive, but research is lacking. Some studies have shown decreased anxiety behavior in rats, and increased activity in osteoarthritic dogs supplemented with CBD, but even less research exists on horses. This study monitored pharmacokinetics and short-term safety for 3 CBD dosages. Eighteen Quarter Horse geldings were randomly assigned to 3 treatment groups: 50 mg (TXT1), 100 mg (TXT2), and 250 mg (TXT3). Dosage was derived from manufacturer recommendations and existing literature on other species. Horses were fed a single dose of CBD pellets. Blood was collected pre- and post-treatment at 0.5, 1, 2, 4 and 12 hr. Serum was analyzed for CBD and serum chemistry, and plasma was analyzed for a complete blood chemistry (CBC) evaluation. Statistics were completed on serum chemistry using PROC MIXED procedure of SAS. Serum chemistry and CBC results were within normal parameters; however, treatment differences were observed for BUN (TXT1=15.50, TXT2=16.52, TXT3=18.61; P≤0.03) and creatinine (TXT1=1.41, TXT2=1.22, TXT3=1.49; P≤0.01). In other species, peak CBD concentrations occur approximately 2 hr post treatment. Peak serum concentrations were detected in 1 of 6 TXT2 horses and 5 of 6 TXT3 horses at 2 hr post treatment. This data can be used to support further research to determine correct and safe doses of CBD in horses.
Recommended Citation
Draeger, Anna L.; Hoffman, Laura K.; Godwin, Patricia R.; Davis, Amanda J.; and Porr, Shea A.
(2021)
"Pharmacokinetics of a Single Feeding of Pelleted Cannabidiol in Horses,"
Steeplechase: An ORCA Student Journal: Vol. 4:
Iss.
2, Article 1.
Available at:
https://digitalcommons.murraystate.edu/steeplechase/vol4/iss2/1
References
Callaway, J. 2004. Hempseed as a nutritional resource: an overview. Euphytica 140: 65-72. Retrieved from: https://link.springer.com/content/pdf/10.1007/s10681-004-4811-6.pdf.
Blake, D.R., Robson, P., Ho. M., Jubb, R.W., McCabe, C.S. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45: 50-52. DOI: 10.1093/rheumatology/kei183
Davis, H.A. 2019. Novel Analgesics and the Impact of Route of Administration in the Horse (doctoral dissertation). Auburn University, Auburn, AL.
De Laurentiis A., Araujo, H.A., Rettori, V. 2014. Role of the endocannabinoid system in the neuroendocrine responses to inflammation. Curr Pharm Des. 20(29): 4697-4706.cRetrieved from:https://anandaenterprises.com.au/wp-content/uploads/2019/12/Role-of- the-Endocannabinoid-System-in-the-Neuroendocrine-Responses-to-Inflammation-1.pdf- 1.pdf
Deabold, K.A., W.S. Schwark, L. Wolf, J.J. Wakshlag. 2019. Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. Animals 832 (9). DOI: 10.3390/ani9100832
Devinsky, O., Verducci, C., Thiele, E.A., Laux, L.C., Patel, A.D., Filloux, F., Szaflarski, J.P., Wilfcong, A., Clark, G.D., Park, Y.D., Seltzer, L.E., Bevin, E.M., Flamini, R., Wechsler, R.T., Friedman, D. 2018. Open-label use of highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy & Behavior 86:131-137. DOI:10.1016/j.yebeh.2018.05.013
Di Marzo, V., Melck, D., Bisogno, T., De Petrocellis, L. 1998. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21(12): 521-528. Retrieved from:http://www.medicalcannabis.com/wp-content/uploads/di_marzo_1998_endocannabinoids.pdf
Ellis, K.L., Contino, E.K. 2019. Treatment using cannabidiol in a horse with mechanical allodynia. Equine Veterinary Education. DOI:10.1111/eve.13168.
Gamble, L.J., Boesch, J.M., Frye, C.W., Schwark, W.S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E.S., Wakshlag, J.J. 2018. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Front. Vet. Sci. 5:165. DOI:10.3389/fvets.2018.00165
Hammell, D.C., Zhang, L.P., Ma, F., Abshire, S.M., Mcllwrath, S.L., Stinchcomb, A.L., Westlund, K.N. 2016. Transdermal cannabidiol reduces inflammation and pain related behaviours in a rat model of arthritis. Eur J Pain 20(6): 936-948. DOI: 10.1016/j.jveb.2012.05.005
Hartsel, J.A., Boyar, K., Pham, A., Silver, R.J., Makriyannis, A. 2019. Cannabis in Veterinary Medicine: Cannabinoid Therapies for Animals. Nutraceuticals in Veterinary Medicine. 121-155. DOI:10.1007/978-3-030-04624-8_10
Hartsel, J.A., Eades, J., Hickory, B., Makriyannis, A. 2016. Cannabis sativa and Hemp. In R.C. Gupta (Ed.), Nutraceuticals Efficacy, Safety and Toxicity. (pp. 735-751). Elsevier Inc. DOI: 10.1016/B978-0-12-802147-7.00053-X.
Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.Pharmacol. Rev 54:161-202. Retrieved from: https://doi.org/10.1124/pr.54.2.161
Jeong, M., Cho, J., Shin, J., Jeon, Y.J., Kim, J.H., Lee, S.J., Kim, E.S., Lee, K. 2014. Hempseed oil induces reactive oxygen species-and C/EBP homologous protein-mediated apoptosis in MH7A human rheumatoid arthritis fibroblast-like synovial cells. Journal of Ethnopharmacology. 154: 745-752. DOI: 10.1016/j.jep.2014.04.052.
Jones, K., Thomas, E., S. Porr. Cannabidiol (CBD) supplementation in horses: A pilot study. Presented at: Posters at the Capitol; ORCA; March 5, 2020. Frankfort, KY.
Kogan, L. R., Hellver, P.W., Robinson, G. 2016 Consumers’ perceptions of hemp products for animals. Journal of American Holistic Veterinary Association. 42: 40-50. Retrieved from: http://www.le-comptoir-malin.com/medias/files/cbd-animaux-ahvma-2016-v42-hemp-article.pdf
Landa, L., Sulcova, A. and Gbelec, P. 2016. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Vet. Med. 61, 111-122. DOI:10.17221/8762-VETMED.
Lodzki, M., Godin, B., Rakou, L., Mechoulam, R., Gallily, R., Touitou, E. 2003. Cannabidiol- transdermal delivery and anti-inflammatory effect in a murine model. Journal of Controlled Release 93: 377-387. DOI: 10.1016/j.jconrel.2003.09.001.
Mackie, K. 2008. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 20 Suppl 1:10-14. DOI:10.1111/j.1365-2826.2008.01671.x
Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., Feldmann, M. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences. 97 (17) 9561-9566. DOI: 10.1073/pnas.160105897.
McPartland, J.M., Matia, I., Di Marzo, V., Glass, M. 2005. Evolutionary origins of the endocannabinoid system. Gene. 370:64-74. DOI: 10.1016/j.gene.2005.11.004.
Pertwee, R.G. 2006. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 30:S13-S18. DOI: 10.1038/sj.ijo.0803272.
Philpott, H.T., O’Brien, M., McDougall, J.J. 2017. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain 158: 2224-2451. DOI: 10.1097/j.pain.0000000000001052.
Russo, R. 2007. History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Chemistry & Biodiversity. 4: 1614-1648. DOI: 10.1002/cbdv.200790144.
Sallaberry, C.A., Astern, L. 2018. The Endocannabinoid System, Our Universal Regulator. JYI. 34(6): 48-55. DOI: 10.22186/jyi.34.5.48-55.
Scuderi, C., Filippis, D., Juvone, T., Blasio, A., Steardo, A., Esposito, G. 2009. Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders. Phytotherapy Research 23: 597-602. DOI: 10.1002/ptr.2625.
Simopoulos, A.P. 2002. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56: 365-379. Retrieved from: https://www.essentialnutrition.com.br/media/artigos/gamalift/21.pdf
Wade, D.T., Makela, P., Robson, P., House, H., Bateman, C. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis. 10:434-441. DOI: 10.1191/1352458504ms1082oa.
Zuardi, A.W. 2006. History of cannabis as a medicine: a review. Brazilian Journal of Psychiatry 28(2): 152-157. DOI:10.1590/S1516-44462006000200015.